CD Targeted Bispecific Antibody Market
完整報告名稱與涵蓋範圍
CD Targeted Bispecific Antibody Market Size, Share & Trends Analysis Report By Target Type (CD3, CD19 and CD30/CD16A), Region And Segment Forecasts, 2025-2034.
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide CD Targeted Bispecific Antibody Market is projected to register a CAGR of 14.5%.
At its core, CD Targeted Bispecific Antibody pertains to a comprehensive analysis, forecast, market dynamics and major trends report covering key market data on th. Stakeholders across the healthcare landscape are mountingly turning to these solutions to meet contemporary demands.
Market momentum is bolstered by mounting appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global CD Targeted Bispecific Antibody Market Snapshot
Chapter 4. Global CD Targeted Bispecific Antibody Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Target Type Estimates & Trend Analysis
5.1. By Target Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Target Type:
5.2.1. CD3
5.2.2. CD19
5.2.3. CD30/CD16A
Chapter 6. CD Targeted Bispecific Antibody Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America CD Targeted Bispecific Antibody Market revenue (US$ Million) estimates and forecasts By Target Type, 2021 - 2034
6.1.2. North America CD Targeted Bispecific Antibody Market revenue (US$ Million) estimates and forecasts by country, 2021 - 2034
6.2. Europe
6.2.1. Europe CD Targeted Bispecific Antibody Market revenue (US$ Million) By Target Type, 2021 - 2034
6.2.2. Europe CD Targeted Bispecific Antibody Market revenue (US$ Million) by country, 2021 - 2034
6.3. Asia Pacific
6.3.1. Asia Pacific CD Targeted Bispecific Antibody Market revenue (US$ Million) By Target Type, 2021 - 2034
6.3.2. Asia Pacific CD Targeted Bispecific Antibody Market revenue (US$ Million) by country, 2021 - 2034
6.4. Latin America
6.4.1. Latin America CD Targeted Bispecific Antibody Market revenue (US$ Million) By Target Type, (US$ Million)
6.4.2. Latin America CD Targeted Bispecific Antibody Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
6.5. Middle East & Africa
6.5.1. Middle East & Africa CD Targeted Bispecific Antibody Market revenue (US$ Million) By Target Type, (US$ Million)
6.5.2. Middle East & Africa CD Targeted Bispecific Antibody Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Aptevo Therapeutics
7.2.2. Affimed GmbH
7.2.3. Sutro Biopharma, Inc.
7.2.4. IGM Biosciences, Inc.
7.2.5. Xencor, Inc.
7.2.6. Amgen Inc.
7.2.7. Genentech USA, Inc.
7.2.8. Astella Pharma Inc.
7.2.9. Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
7.2.10. Merus
7.2.11. Regeneron Pharmaceuticals, Inc.
7.2.12. Other Key Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們